In 2045, more than 50% of the US population will be Hispanic, Black, Asian and multiracial—up from about 40% today. Yet, despite laws requiring the NIH to include more minorities and women in studies, most trial participants are white. Even in respiratory disease, which disproportionately affects African Americans, minority subjects were included in just 1.9% of studies. The healthcare industry as a whole has an opportunity to correct this imbalance in clinical research, knowing it will be difficult to realize the goals of personalized medicine without better ethnic, racial and gender representation in trials. Moderated by a behavioral scientist, this expert panel will address barriers to research and share best practices to ensure more representative clinical trial participation.